NCT05824169: Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 18 planned
- Started
- 25 Feb 2023
- Primary completion
- Dec 2026
- Arms
- Low dosage group, High dosage group
- Results
- None posted
- 25 Feb 2023: Trial started
- 21 Apr 2023: Trial registered